Episode 4: Investing Wisely in Bioprocessing

The shift from high-volume drugs to niche biologics requires a more than just expanded footprints, it demands smarter bioprocess controls, lower COGs early on in development, and cross-functional teams. Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/infraction/infrared License code: KOVHBGC4J4UADISK